"Aimovig provides patients with a novel option for reducing the number of days with migraine," said Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "We need new treatments for this painful and often debilitating condition."

Patients often describe migraine headache pain as an intense pulsing or throbbing pain in one area of the head. Additional symptoms include nausea and/or vomiting and sensitivity to light and sound. Approximately one-third of affected individuals can predict the onset of a migraine because it is preceded by an aura—transient sensory or visual disturbances that appear as flashing lights, zig-zag lines or a temporary loss of vision. People with migraine tend to have recurring attacks triggered by a number of different factors, including stress, hormonal changes, bright or flashing lights, lack of food or sleep and diet. Migraine is three times more common in women than in men and affects more than 10 percent of people worldwide.

The effectiveness of Aimovig for the preventive treatment of migraine was evaluated in three clinical trials. The first study included 955 participants with a history of episodic migraine and compared Aimovig to placebo. Over the course of six months, Aimovig-treated patients experienced, on average, one to two fewer monthly migraine days than those on placebo. The second study included 577 patients with a history of episodic migraine and compared Aimovig to placeb.
Over the course of three months, Aimovig-treated patients experienced, on average, one fewer migraine day per month than those on placebo. The third study evaluated 667 patients with a history of chronic migraine and compared Aimovig to placebo. In that study, over the course of three months, patients treated with Aimovig experienced, on average, 2 ½ fewer monthly migraine days than those receiving placebo.

The most common side effects that patients in the clinical trials reported were injection site reactions and constipation.

The FDA granted the approval of Aimovig to Amgen Inc.

To receive daily emails from Breaking Christian News to your inbox CLICK HERE

Good News: TPUSA High School Clubs More Than Double, Hit 2,700 Nationwide

Atheist Bill Maher Condemns Media Silence on Christian Genocide in Nigeria: 'Systematic Killing'

'We Found Him': The Alleged Smoke Bomber Who Disrupted a Sean Feucht Worship Event; His Shocking Links to Antifa Inside Canada's Military

As Deadly Violence against Houses of Worship Rises, So Do Law Enforcement, Security Measures

Portland Police Arrest Conservative Journalist Nick Sortor Outside ICE Facility, 'But None of the Domestic Terrorists'

Apple Takes Down ICE Tracking Apps After Pressure from Bondi DOJ

Kash Patel's FBI Cuts All Ties to Southern Poverty Law Center

The President Is Already Using the Shutdown to Slash Federal Spending, Plans to Make Job Cuts

Israeli Leaders React to Terror Attack on UK Synagogue as Navy Intercepts Pro-Hamas Flotilla

President Trump Sets Sunday Deadline for Hamas to Accept Deal or Face 'ALL HELL'

Hamas Says It Will Release All Remaining Hostages, But...

'Blown Away': Hundreds Saved and Baptized as 8,000 Students Seek Jesus at University of Tennessee

Concerned Citizens Checked Their 'Conservative' Town High School Library for These Obscene Books Available to Students; Here's What Happened

DOJ Investigates Major School District Over DEI Programs

RFK Jr. Directs FDA to Study the Safety of Abortion Pills

Planned Parenthood Closes Houston Abortion Facility That Was Biggest in America

Democrat Prosecutor Sued after Dropping Charges against Woman Who Violently Assaulted Pro-Lifer

Kilmar Abrego Garcia's Final Order of Removal Stands as Judge Denies Motion to Reopen His Case

Gov't Shutdown Continues: White House Releases New Memo Exposing Dems' Demand for Nearly $200 B in Taxpayer-Funded Healthcare for Illegal Immigrants

Watch: Faith Revival Follows Charlie Kirk's Death As More People Attend Church and Read the Bible; 'This Is Bigger Than Charlie Kirk'